Description
Retevmo Uses
Retevmo (Selpercatinib) is a kinase inhibitor used for the treatment of:
- Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Side Effects: The most commonly reported retevmo side effects (≥ 25%) include:
- Decreased calcium
- Dry mouth
- Diarrhea
- Increased creatinine
- Hypertension
- Fatigue
- Edema
- Decreased
- Platelets
- Increased total cholesterol
- Rash
- Decreased sodium
- Constipation
- Increased alkaline phosphatase
Warnings and Precautions:
- Monitor ALT and AST prior to initiating retevmo 80 mg capsule, every 2 weeks during the first 3 months, then monthly thereafter.
- Optimize blood pressure prior to initiating therapy with retevmo 40 mg. Monitor blood pressure after 7 days, at least monthly thereafter.
- Assess patients who are at significantly higher risk of developing QTc prolongation, including those with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure.
- Do not administer selpercatinib capsules for at least 2 weeks following major surgery and until adequate wound healing.
- On behalf of findings from animal reproduction studies and its mechanism of action, retevmo capsules can cause fetal harm if administered to a pregnant woman.
- Respective women should not breastfeed during treatment with retevmo dosage and for 1 week following the final dose.
